Exact Sciences Co. (NASDAQ:EXAS) Receives $72.94 Consensus PT from Analysts

Exact Sciences Co. (NASDAQ:EXAS) has received an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $72.94.

A number of equities research analysts have recently issued reports on EXAS shares. Stifel Nicolaus reduced their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group cut their price objective on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Jefferies Financial Group raised their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. TD Cowen boosted their price target on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Citigroup dropped their price objective on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th.

Exact Sciences Stock Down 0.3 %

Shares of EXAS opened at $56.50 on Wednesday. The firm has a market cap of $10.46 billion, a P/E ratio of -48.29 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62. The firm’s 50-day simple moving average is $58.09 and its 200 day simple moving average is $58.56.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm’s revenue for the quarter was up 12.8% compared to the same quarter last year. On average, analysts forecast that Exact Sciences will post -1.13 earnings per share for the current year.

Insiders Place Their Bets

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction that occurred on Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This trade represents a 1.85 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.36% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

A number of institutional investors have recently made changes to their positions in EXAS. Huntington National Bank boosted its holdings in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of Exact Sciences in the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP bought a new stake in shares of Exact Sciences in the 3rd quarter valued at $35,000. Vestor Capital LLC acquired a new stake in shares of Exact Sciences during the third quarter worth $46,000. Finally, V Square Quantitative Management LLC bought a new position in Exact Sciences during the third quarter worth $47,000. Institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.